Enrique Grande: Cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma
Enrique Grande, Head of Oncology at MD Anderson Madrid Cancer Center, recently shared a post on X:
“Investigating cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma after prior immunotherapy.
Results show similar time to next therapy and overall survival for both regimens, aligning with phase 3 CONTACT-03 trial results.”
Authors: Georges Gebrael MD, Yeonjung Jo MS, Vinay Mathew Thomas MD, Haoran Li MD, PhD, Nicolas Sayegh MD, Nishita Tripathi MD, Ayana Srivastava, Blake Nordblad MSCR, Emre Dal MD, Arshit Narang MBBS, James Brundage MS, Patrick Campbell MD, Gliceida Galarza Fortuna MD, Chadi Hage Chehade MD, Benjamin L. Maughan MD, PharmD, Neeraj Agarwal MD, FASCO, Umang Swami MD, MS
Source: Enrique Grande/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023